Introduction:In recent years, the approach to adjuvant therapy for rectal cancer in the United States and Europe has been shifting toward preoperative therapy to promote sphincter-preserving surgery and decrease acute and late bowel toxicity. Patients&Methods:This study will be a phase II trial to study the effectiveness of combining chemotherapy (Gemcitabine) and external -beam radiotherapy followed by surgery in treating patients who have locally advanced rectal cancer , It is carried on Sohag University Hospital & Sohag NCI since( October 2014-December2017),the dose of radiotherapy 5040 cGy /28ttt,and chemotherapy dose is 45mg/m2 given twice weekly during radiotherapy sessions only, the study included 30 patients (age 18 and over), having rectal cancer with the following eligibility criteria:histologically proven ,previously untreated rectal carcinoma , every patient in the study was subjected to the following:history & physical examination,laboratory investigations, radiological studies. Results:Thirty patients were included in the study,13 females (43.3%) and 17 male( 56.6%) mean of the age was 49 years. (range24-65year), most of them had adenocarcinoma of the rectum, the main presenting symptom was bleeding per rectum(56.7%), as regard to the response to the neoadjuvant treatmen 12/30 patients (40%) achieved Partial response, 8/30patients(27.6%) achieved complete response and 10/30 patients (33%) had no response, abdomino -perineal resection was performed in 19 patients(63.3%) and 11 patients (36.7%) underwent sphincter preservation operation, about the toxicity in this study,for chemotherapy diarrhea was the most common manifestation which seen in 25 patients(83%),followed by loss of appetite seen in 9 patients(63.3%), for radiotherapy 19 patients (63%) developed wet desquamation. the rate of Overall Survival of the 2-years study is (80%),the Disease free survival is (63%)while the progression free survival is (72%),N stage was the only significant factor affecting the disease free survival and overall survival. Conclusion: Pre-operative chemo-radiotherapy in dose and fractionation schedule used is safe, effective and well tolerated, allowed sphincter preservation which performed in (36.7%) of patients
Introduction
There is increasing use of preoperative chemor-adiotherapy as a component of combined-modality treatment (CMT) for clinically resectable rectal cancer. 
Radiotherapy:
Target volume: Target volume included the rectum and the draining lymph node chains (pararectal, hypogastric, presacral lymph nodes) up to S1-S2 junction. Dose and energy: all patients were treated by photon 6 MeV generated from linear accelerator. The dose was 5040 cGy in 28 fractions over5 weeks.
Chemotherapy:
Gemcitabine was prescribed at 45mg/m2 given twice weekly during radiotherapy sessions only. Reassessment: 4-6 weeks after completion of chemo-radiation therapy,all patients will re-evaluated by CBC, CEA, digital rectal examination, CT or MRI of pelvis and abdomen and proctoscopy to evaluate patients for the possibility of surgery.this includes; a)Re-staging by TNM clinical staging. b)Assessment of tumor response.
Surrgey:
After re-staging, all patients were subjected to surgery in the form of abdominally assisted trans-anal coloanal pull through as a sphincter preserving procedure or to abdominoperineal resection. Toxicity: Acute and chronic toxicity was evaluated according to Common Terminology Criteria for Adverse Events(CTCAE).
Results
The study showed that the mean age of the study patients was 46.8±10.8 years, with a range from 24 to 65, a little more than half of the cases were males (17 case, 57%) with only 13 cases (43%) were females. Nearly half of the cases in our study were from urban regions (16 cases, 53%) and the other half were rural (14 cases, 47%). Regarding the clinical presentation, bleeding per rectum was the most common presenting symptom representing(56.7%),followed by colic(16.7%),Diarrhea (13.3%),Tenesmus(10%) and vomiting(3.3%) , According to Karnofsky performance status about (20% ) of patients have PS 70%,while (80%) 0f patients have PS > 70%, Regarding the staging, the majority of cases were either stage T3 or T4 (40% each), with only 6 cases were in stage T2 (20%). Most of cases were in stage N+ (positive LN involvement), with only 7 cases were in stage N0 (23.3%). In the study of Tey et al., (2017) 90% . Regarding tumor localization from anal verge; it was so near (<5 cm) in 30% of cases, and so far (>10 cm) in 20% of them. The remaining half of cases were in between the two extremes (5-10 cm from anal vetage). Regarding pathology in our study, the most frequent pathology was adenocarcinoma (26 cases),the histologic grading was; MDA, seen in 13 cases WDA (7 cases, 23.3%), then PDA (6 cases, 20%), The others were; SRC (2 cases, 6.7%), and lastly mucoid and mucinous carcinoma (1 cases each) Similarly ; (43.3%). This was followed by WDA (7 cases, 23.3%), then PDA (6 cases, 20%), The others were; SRC (2 cases, 6.7%), and lastly mucoid and mucinous carcinoma (1 cases each) Similarly. The most common histologic tumor grade was MDA(43.3 %,) followed by WDA( 23.3% ) and lastly PDA(20%). As regard to the acute toxicity in our the GIT toxicity grade 1&2 was in 20% of patients and grade 3 was in 16% of the patients . There were no significant differences between males and females regarding demographic, clinical or therapeutic data. The only two exceptions were clinical presentation (with more bleeding per rectum,vomiting and diarrhea among females and tumor location from the anal verge, where females had nearer tumor localization compared to males. There was no significant relation between response to chemotherapy and each of age of the patients, sex, disease pathology, tumor stage. , while there was significant relation between response to chemotherapy and tumor localization, with cases with farer localization tend to be CR more than those with shorter distance from anal verge. We found that there was no significant relation between overall survival of the patients and their demographic and clinical characteristics. The only exception was the N stage, where patients with negative lymph nodes had longer survival.
Discussion
Our study showed that the mean age of the study patients was 46.8±10.8 years, with a range from 24 to 65 years. Our cases were generally younger than those cases studied by Tey et al., (2017) as 90% of their cases were older than 50 years old. In our study, a little more than half of the cases were males (17 case, 57%) with only 13 cases (43%) were females. This was similar to the data recorded by Korkolis et al., (2007) where males accounted for 53% of their cases. Males were over 65% o Nearly half of the cases in our study were from urban regions (16 cases, 53%) and the other half were rural (14 cases, 47%). Regarding the clinical presentation of our study, bleeding per rectum was the most common presenting symptom representing(56.7%),followed by colic(16.7%),Diarrhea (13.3%),Tenesmus(10%) and vomiting(3.3%).
In our study according to Karnofsky Positive lymph nodes were seen in 85% of their cases. Similarly, the study of Kairevičė et al., (2017). Regarding tumor localization from anal verge; it was so near (<5 cm) in 30% of cases, and so far (>10 cm) in 20% of them. The remaining half of cases were in between the two extremes (5-10 cm from anal vetage). This was nearly the same as the results of Hess et al., (2017). As regard to the acute toxicity in our study the GIT toxicity grade 1&2 was in 20% of patients and grade 3 was in 16% of the patients and that was more or less comparable to those reported by Ouf & Kamel et al; 2oo2 . As regard to the surgical complications in our study it seems acceptable,with no post-operative deaths which is similar to Gerard et al;2003 . Regarding response to CRT, CR was seen in 8 cases (27%), with the remaining 22 cases either PR or stationary (12 and 10 cases, respectively). The study of Korkolis et al., (2007) showed that the overall response was recorded in 25 patients (84%). 5 patients (17%) had complete response, 8 patients (27%) showed microscopic residual disease and 12 patients (40%) had macroscopic residual disease after treatment.
Conclusion
Pre-operative chemo-radiotherapy in dose and fractionation schedule used in the present study is safe, effective and well tolerated. Pre-operative chemo-radiotherapy allowed sphincter preservation in the form of Trans-anal abdominally assisted colon-anal pull-through was performed in (36.7%) of patients And (63.3%) of patients underwent Abdomino-Perineal resection. Pre-operative chemo-radiotherapy allowed curative surgery as survival and regards tumor response to neoadjuvant therapy; which was 26.7% achieved complete response,40% achieved partial response and 33% are stationary. the only significant prognostic factor affecting disease free survival and overall survival was N staging. The rate of overall survival in the study is 80%, disease free survival is 63% and progression free survival is 72%. Regarding response to CRT, CR was seen in 8 cases (27%), with the remaining 22 cases either PR or stationary (12 and 10 cases, respectively). As regard the DFS was achieved for 63% of patients while the PFS and OS rate was 72% and 80% of patients respectively. There were no significant differences between males and females regarding demographic, clinical or therapeutic data. The only two exceptions were clinical presentation (with more bleeding per rectum,vomiting and diarrhea among females and tumor location from the anal verge, where females had nearer tumor localization compared to males. There was no significant relation between response to chemotherapy and each of age of the patients, sex, disease pathology, tumor stage. , while there was significant relation between response to chemotherapy and tumor localization, with cases with farer localization tend to be CR more than those with shorter distance from anal verge. We found that there was no significant relation between overall survival of the patients and their demographic and clinical characteristics. The only exception was the N stage, where patients with negative lymph nodes had longer survival. 
